The Patent Finder

Revopsis Holdings, LLC

9 patents currently held · Updated Nov 19, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
5
Ending by 2030
May 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Apr 27, 2027
    The maintenance fee for Neutralizing Molecules to Viral Antigens (US 9,169,318) comes due Apr 27, 2027. Unpaid by Oct 27, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 9 of 9

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 8,148,085Donor Specific Antibody Libraries
In force
 · Medium confidence
In forceMedium confidence
US 10,216,897Design and Construction of Diverse Synthetic Peptide and Polypeptide Libraries
In force
 · Medium confidence
In forceMedium confidence
US 8,114,967Constructs and Libraries Comprising Antibody Surrogate Light Chain Sequences
In force
 · High confidence
In forceHigh confidence
US 10,214,580Constructs and Libraries Comprising Antibody Surrogate Light Chain Sequences
In force
 · Medium confidence
In forceMedium confidence
US 8,131,480Construction of Diverse Synthetic Peptide and Polypeptide Libraries
In force
 · High confidence
In forceHigh confidence
US 8,969,082Expression of Surrogate Light Chains
In force
 · High confidence
In forceHigh confidence
US 9,169,318Neutralizing Molecules to Viral Antigens
In force
 · Medium confidence
In forceMedium confidence
US 10,300,140Sur-Binding Proteins Against ERBB3
In force
 · High confidence
In forceHigh confidence
US 9,975,956Surrogate Binding Proteins Which Bind DR4 And/Or DR5
In force
 · High confidence
In forceHigh confidence

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited